Dan Costin, MD

Hematology & Oncology
2 Longview Avenue, Suite 300, White Plains, NY 10601
(914) 849-7630
(914) 849-7694

Biography

Dr. Dan Costin is Director of the White Plains Hospital Center for Cancer Care. He has been practicing medical oncology and hematology in Westchester since 1993. He received his B.S. in biochemistry at the University of California in Los Angeles and his medical degree at the University of California in San Francisco. He completed his internal medicine residency at Beth Israel Hospital in Boston in 1990, his fellowship in medical oncology at the National Cancer Institute in Bethesda in 1991, and his fellowship in hematology at New York University in 1993. He has been an attending physician at White Plains Hospital since 1993 and served as section chief of the department of Hematology-Oncology from 1999 to 2007.

 

Dr. Costin is the founding member of Cancer and Blood Specialists of New York (CAB-SNY) and continues to this day as its medical director. After the Dickstein Cancer Treatment Center was completed in 1999, he relocated CAB-SNY into the newly designed free standing cancer center. He is one of the sentinel members of the White Plains Hospital Cancer Program and presently serves as co-medical director of the Program. He was chairperson of the Multidisciplinary Tumor Board Conference for 15 years, presiding over 750 meetings, at which time over 3,000 patients were presented and discussed.

Read More Show Less

Dr. Costin has always had an active interest in research.  He has been principal investigator or co-investigator on over 100 different protocols offered at the White Plains Cancer Program over the past 20 years. He is the principal investigator on the following studies that are presently open at the Center for Cancer Care at White Plains Hospital:

 

Advanced solid malignancies:

  • STRONG protocol: an open-label, multi-center safety study of fixed-dose durvalumab and tremelimumab combination therapy or durvalumab monotherapy in advanced solid malignancies.

 

Bladder cancer:

  • STRONG bladder cancer protocol: safety study of fixed-dose durvalumab for patients with urothelial and non-urothelial carcinoma.

 

Breast cancer:

  • NSABP-B55: A Randomized double-blind Placebo-controlled multi-center Phase III study to assess the efficacy and safety of Olaparib versus placebo as adjuvant treatment in patients with Germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer.
  • S1418: A Randomized phase III trial to evaluate the efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with >/=1 cm residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy.
  • GSK201973: A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer.

 

Gynecologic cancer:

  • NRG-GY004: A phase III study comparing single-agent Olaparib or the combination of cediranib and Olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
  • NRG-GY-005: A randomized phase II/III study of the combination of cediranib and Olaparib compared to cediranib or Olaparib alone, or standard of care chemotherapy in women with recurrent platinum-resistant or –refractory ovarian, fallopian tube, or primary peritoneal cancer.

 

Liver cancer:

  • MK-3475-Keynote240: A phase III study of pembrolizumab versus best supportive care as second-line therapy in subjects with previously systemically treated advanced hepatocellular carcinoma.

 

Lung cancer:

  • CA209-CHECKMATE370: A master protocol of phase ½ studies of nivolumab in advanced NSCLC using nivolumab as maintenance after induction chemotherapy or as first-line treatment alone or in combination with standard of care therapies.
  • MK3474-Keynote407: A randomized double blind phase III study of carboplatin-Paclitaxel/Nab-paclitaxel chemotherapy with or without pembrolizumab in first line metastatic squamous non-small cell lung cancer.
  • Lung biopsy study: Next generation DNA sequencing of malignant tumors obtained by Lung biopsy – a prospective clinical registry.

 

Malignant melanoma:

  • E3612: A randomized  phase II trial of Ipilimumab with or without Bevacizumab in patients with unresectable stage III or stage IV melanoma.

 

Myelodysplastic syndrome (MDS) / acute myeloid leukemia (AML):

  • Onconovoa 09-08: Phase I/II, multi-center, dose-escalating study of the tolerability, pharmacokinetics, and clinical activity of the combined administration of oral rigosertib with azacitidine in patients with MDS or AML.

 

Prostate cancer:

  • S1216: A phase III randomized trial comparing androgen deprivation therapy + TAK-700 with androgen deprivation therapy + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer.

 

Renal cancer:

  • EA8143 (PROSPER RCC): A phase III randomized study comparing perioperative nivolumab versus observation in patients with localized renal cell carcinoma undergoing nephrectomy.

 

Sarcoma:

  • A091304: A phase I/II randomized study of MLN0128 versus Pazopanib in patients with locally advanced unresectable and/or metastatic sarcoma.

 

Supportive and complementary care:

  • DEALS-EPS: Dietary education and livestrong exercise program study.
  • Tommie Copper: Pilot evaluation of Tommie copper material and its impact on pain control.

 

Dr. Costin is also a co-investigator on several other open studies at Center for Cancer Care at White Plains Hospital, including:

  • A011106: alternate approaches for clinical stage II or III estrogen receptor positive breast cancer in postmenopausal women.
  • AO11401: trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer.
  • A011502: randomized phase III double-blinded trial of aspirin as adjuvant therapy for node positive HER2 negative breast cancer – the ABC trial.
  • E2112: randomized phase III trial of endocrine therapy plus entinostat/placebo in postmenopausal patients with hormone receptor positive advanced breast cancer.
  • NRG-BR003: randomized study of adjuvant therapy comparing AC followed by paclitaxel with our without carboplatin for node-positive or high-risk node-negative triple negative invasive breast cancer.
  • S1207: phase III randomized clinical trial evaluating adjuvant endocrine therapy +/- one year of everolimus in patients with high-risk hormone receptor-positive and HER2 negative breast cancer.
  • S1416: phase II randomized placebo-controlled trial of cisplatin with or without Veliparib in metastatic triple-negative breast cancer and/or BRCA mutation-associated breast cancer.
  • A081105: randomized double blind placebo controlled study of erlotinib or placebo in patients with completely resected EGFR mutant non-small cell lung cancer.
  • A151216: Adjuvant lung cancer enrichment marker identification and sequencing trial (ALCHEMIST).
  • E4512: phase III double-blind trial for surgically resected early stage non-small cell lung cancer – crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein.
  • EA5142: A randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancer (ANVIL).
  • E3106: randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.
  • S1513: randomized phase II study of 2nd line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib).
  • EAY131: molecular analysis for therapy choice (MATCH).

Dr. Costin lives in White Plains with his wife Sandra and their two beautiful children, Diana and Jeremy. He enjoys golf, art, photography, opera, and literature.

 

Recent Patient Comments

Press Ganey
"https:\/\/api.binaryfountain.com\/api\/service\/bsr\/comments?personId=1033103155&perPage=999"
5
01/28/2024
Can't be better.Dr Costin and staff is thorough, kind and brilliant
5
01/17/2024
Excellent
5
01/14/2024
Completely satisfied
5
01/11/2024
God Bless Dr Costin he is great
5
01/02/2024
Already recommended. Feel confident in Dr and it's a comfort during a hard time to know he is handling my care.
5
12/26/2023
I'm always handled with care.
5
12/26/2023
The care provided by Dr. Costin and his staff is second to none.all make the patient feel comfortable and well cared for.
5
12/24/2023
Dr. Is an excellent physician. I'm blessed that I have him as my physician and feel he is giving me the best treatment possible for my cancer.
5
12/21/2023
Everything was positive. Explained to me in a way that I could understand. I didn't feel rushed or like I'm just another number. It was a nice family feeling.
5
12/18/2023
Dr Costin saves lives, mine being one of them.
5
12/14/2023
Excellent
5
12/14/2023
I always have my appointments with Dr. Costin to be excellent. He is very caring and knowledgeable, and I feel comfortable asking him anything concerning my general well being.
5
12/11/2023
There is no other doctor like Dr. Costin. He is the best! And I see many doctors on a regular basis.
5
12/06/2023
Always get the best care -
5
11/04/2023
Wonderful Dr. very thorough.
5
10/29/2023
I would recommend Dr. Costin without ANY hesitation. He is an amazing doctor and a tremendous human being which is a challenge to find these days.
5
10/24/2023
*Dr. Costin & NP & their staff are excellent providers. They take the time to listen to all your questions & concerns.
5
10/20/2023
*Dr. Costin is an extremely dedicated doctor, who loves his profession. He is kind, caring and was born to be a doctor. He's the absolute BEST!
5
10/18/2023
*Dr. Costin is brilliant. He is outstanding in every way. He is compassionate, understands everything and explains it all so well. He is a 10+.
4.67
10/12/2023
It was a good experience. Dr. Costin explained every thing to me very clearly. He does an excellent job.
5
10/06/2023
I have been seeing Dr. Costin for many years. He is as skilled and caring and genial as any doctor you might hope be treated by. He always has time to explain medical matters and even to just talk about mutually interesting subjects. This day two time factors came up, which is rare: He had to spend more time with a previous patient and I suddenly needed to leave a little earlier than expected. I explained that to the nurse and, surprisingly, Dr. Costin managed to visit me fairly soon, cover all items with ease, and allow me and I hope him to get to our next destinations. That's in addition to his being an exceptional doctor who inspires the highest confidence in a patient.
5
09/20/2023
Very satisfactory
5
09/18/2023
Always excellent
5
09/18/2023
Good
5
09/14/2023
Dr. Dan Costin is a superb, outstanding Doctor. He puts his patient first and at ease. A compassionate individual. I trust only him!
5
09/11/2023
*Dr. Costin is very thorough & patient.
5
09/08/2023
Excellent communication
5
08/30/2023
*Doctor Costin has been my oncologist for 25 years - need I say more.
5
08/08/2023
*Dr. Dan Costin is a very special doctor, who never treats anyone like a "file folder" or just a "case"! He cares about us, is so kind, and serves us both medically and mentally under his care! Thank you!!!
4.67
08/04/2023
I did very good.
5
08/02/2023
Dr. Costin is so thorough and does not rush me. He explains everything really well.
5
07/31/2023
Dr. COSTIN IS A WONDERFUL PHSICIAN: VERY SMART, KIND, AND CONSIDERATE.
5
07/29/2023
There is no better Dr. Than Dr. Costin
5
07/18/2023
Dr Costin couldn't have been more knowledgeable or caring!
5
07/10/2023
Wonderful experience. Gives me piece of mind. So professional, courteous & kind. A pure pleasure.
5
06/30/2023
*Dr. Costin is an outstanding oncologist with such a caring, kind bedside manner. He is #1 in my book!
5
06/20/2023
Very excellent service
5
05/24/2023
Everything is fine
5
05/14/2023
Have had a very positive 23 year relationship with Dr. Costin.
5
05/01/2023
The doctor is very knowledgeable and caring. I am fortunate to be under his care.
5
04/26/2023
Dr Costin and team very professional.
4
04/26/2023
They are very friendly
5
04/24/2023
Good
5
04/23/2023
This is an outstanding team of providers
5
04/10/2023
The dr. was very thorough going over previous appointments/scans & future appointments, scans, etc., we discussed everything.
5
04/07/2023
My doctor, *Dr. Costin is a wonderful doctor. Very caring and very efficient.

    In The News

    Read more news at Health Matters, a White Plains Hospital publication.

    Education & Training

    Medical Degree
    • University of California, San Francisco
    Post-graduate Training
    • Fellowship, Medical Oncology - National Cancer Institute, Bethesda
    • Fellowship, Hematology - New York University, New York
    • Residency, Internal Medicine - Beth Israel Hospital, Boston
    Board Certification(s)
    • American Board of Medical Oncology
    • American Board of Hematology
    • American Board of Internal Medicine
    Membership(s)
    • American College of Physicians
    • American Medical Association
    • American Society of Hematology
    • American Society of Clinical Oncology
    • Massachusetts Medical Society

    Institutional Affiliations

    • White Plains Hospital
    • Burke Rehabilitation Hospital
    Dan Costin, MD
    Schedule an Appointment

    Overall Satisfaction

    4.9 / 5
    220 Ratings | 46 Comments
    Aggregate Rating
    Doctor's Award